A woman's experience of tapering from buprenorphine during pregnancy

BMJ Case Reports

Volumn 2014, Issue , 2014, Pages

  Welle Strand, Gabrielle Katrine ^a,b   Kvamme, Odd ^c   Andreassen, Andreas ^c   Ravndal, Edle ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Norwegian Directorate of Health   (Norway)

^c Leirvik Legekontor ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; OPIATE; PARACETAMOL; PROMETHAZINE; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT;

ADULT; APPETITE DISORDER; ARTICLE; CANNABIS USE; CASE REPORT; CLINICAL FEATURE; DRUG DEPENDENCE TREATMENT; DRUG DOSE REDUCTION; DRUG USE; FEMALE; GESTATIONAL AGE; HUMAN; LOOSE FECES; MENTAL DISEASE; OPIATE ADDICTION; OPIOID MAINTENANCE TREATMENT; PAIN; PREGNANCY OUTCOME; PREGNANT WOMAN; RATING SCALE; SCORING SYSTEM; SLEEP DISORDER; SMOKING CESSATION; SNEEZING; SWEATING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; BIRTH; COMPLICATION; FETUS; MALE; NEWBORN; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATIONS; SUBSTANCE WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; FETUS; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MALE; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PARTURITION; PREGNANCY; PREGNANCY COMPLICATIONS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84938886029     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2014-207207     Document Type: Article

References (22)

1. Welle-Strand GK, Bakstad B. National clinical guideline for opioid maintenance treatment in pregnancy and the follow-up of the children and families until school-age. Norwegian Directorate of Health, 2011.
2. Medication-assisted treatment for opioid addiction during pregnancy. In: TIP 43. 11/2008:217-218. Substance Abuse and Mental Health Services Administration.
3. Jones HE. Treating opioid use disorders during pregnancy: historical, current, and future directions. Subst Abus 2013;34:89-91.
4. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-31.
5. Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend 2013;127:200-6.
6. Dryden C, Young D, Hepburn M, et al. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009;116:665-71.
7. Dashe JS, Jackson GL, Olscher DA, et al. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92:854-8.
8. Tommervik K, Walhovd KB, TO A, et al. Offer tapering of the OMT-medication instead of maintenance treatment in pregnancy (Norwegian only: Tilby nedtrapping i stedet). In: Bergens Tidende. 2011.
9. The methadone-babies: Born intoxicated, paid by the State (Norwegian only: Metadonbarna: Født på rus betalt av staten).
10. Dommerud T. Bringing the methadone-babies to the Norwegian parliament (Norwegian only: Metadonbarna til Stortinget). In: Aftenposten. 2011.
11. Vindegg G. Methadone maintenance to pregnant women; are the government giving the right advice? (Norwegain only: Metadon til gravide: Veiledning eller villedning). Tidsskrift for Norsk Psykologforening 2012;49:896-7.
12. M: Blog: Pregnant and on buprenorphine (Norwegian only: Gravid i LAR). http://www.gravidilar.blogg.no
13. Juliussen PB, Vinsjansen S, Nilsen B, et al. Måling av vekst og vekt: En oversikt over anbefalte teknikker. Pediatrisk Endokrinologi 2005;19:23-9.
14. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5:47-55.
15. Kreek MJ. Methadone disposition during the perinatal period in humans. Pharmacol Biochem Behav 1979;11(Suppl):7-13.
16. Shiu JR, Ensom MH. Dosing and monitoring of methadone in pregnancy: literature review. Can J Hosp Pharm 2012;65:380-6.
17. Kornor H, Waal H. From opioid maintenance to abstinence: a literature review. Drug Alcohol Rev 2005;24:267-74.
18. Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction 2012;107:1621-9.
19. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? [see comment]. J Subst Abuse Treat 2003;24:363-7.
20. McCarthy JJ. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med 2012;25:109-12.
21. Mulder EJ, Robles de Medina PG, Huizink AC, et al. Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early HumDev 2002;70:3-14.
22. Weinstock M. The long-term behavioural consequences of prenatal stress. Neurosci Biobehav Rev 2008;32:1073-86.